EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

February 1, 2027

Conditions
Intervertebral Disc Degeneration
Interventions
DRUG

aNPC

Eligible subjects must be diagnosed with disc herniation and scheduled for discectomy, nucleus pulposus tissue will be collected for cell culture. Cultured cells will be then reintroduced into the degenerated disc via injection. Subjects will undergo multiple follow-up visits after surgery to evaluate safety and efficacy, supplemented with imaging studies to assess disc height, tissue regeneration, and water-retention capacity.

All Listed Sponsors
lead

ASTEROGENE Biomedical Co. Ltd.

INDUSTRY

NCT07168603 - EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease | Biotech Hunter | Biotech Hunter